Multivariate analysis for RFS at 3 years after alloHCT
| Multivariable analysis with variables at diagnosis . | HR . | Lower CI . | Upper CI . | P value . |
|---|---|---|---|---|
| DNMT3A comutation (vs not) | 2.64 | 1.20 | 5.79 | .016 |
| ICC-defined TP53mut MN (vs does not meet) | 1.81 | 0.95 | 3.46 | .07 |
| Non-DBD TP53mut only (vs ≥1 DBD mutation) | 3.40 | 1.44 | 8.06 | .005 |
| CK (vs no CK) | 1.14 | 0.58 | 2.27 | .7 |
| Multivariable analysis with variables at diagnosis . | HR . | Lower CI . | Upper CI . | P value . |
|---|---|---|---|---|
| DNMT3A comutation (vs not) | 2.64 | 1.20 | 5.79 | .016 |
| ICC-defined TP53mut MN (vs does not meet) | 1.81 | 0.95 | 3.46 | .07 |
| Non-DBD TP53mut only (vs ≥1 DBD mutation) | 3.40 | 1.44 | 8.06 | .005 |
| CK (vs no CK) | 1.14 | 0.58 | 2.27 | .7 |
| Multivariable analysis with variables at pre-alloHCT . | HR . | Lower CI . | Upper CI . | P value . |
|---|---|---|---|---|
| Cytogenetic response | ||||
| CK at diagnosis, but not pre-alloHCT (vs no CK) | 1.41 | 0.67 | 2.96 | .36 |
| CK pre-alloHCT (vs no CK) | 1.72 | 0.81 | 3.66 | .16 |
| Melphalan-based conditioning (vs no melphalan) | 0.52 | 0.33 | 0.82 | .005 |
| PTCy-based GVHD prophylaxis (vs not) | 1.25 | 0.71 | 2.20 | .43 |
| Pre-alloHCT BM blasts ≥5% (vs <5% blasts) | 2.76 | 1.33 | 5.34 | .006 |
| Multivariable analysis with variables at pre-alloHCT . | HR . | Lower CI . | Upper CI . | P value . |
|---|---|---|---|---|
| Cytogenetic response | ||||
| CK at diagnosis, but not pre-alloHCT (vs no CK) | 1.41 | 0.67 | 2.96 | .36 |
| CK pre-alloHCT (vs no CK) | 1.72 | 0.81 | 3.66 | .16 |
| Melphalan-based conditioning (vs no melphalan) | 0.52 | 0.33 | 0.82 | .005 |
| PTCy-based GVHD prophylaxis (vs not) | 1.25 | 0.71 | 2.20 | .43 |
| Pre-alloHCT BM blasts ≥5% (vs <5% blasts) | 2.76 | 1.33 | 5.34 | .006 |
Boldface values indicate statistically significant at P < 0.05.